Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064438 | 0.71 | CYP1A2 (0.49) | LMNAALDH1A1KDM4EMAPT | |
| SCHEMBL6376648 | 0.68 | CHRNB2 (0.51) | — | |
| SCHEMBL7107729 | 0.67 | CYP2C19 (0.37) | SMN1; SMN2KCNA5ALDH1A1KDM4EMAPT | |
| SCHEMBL3371141 | 0.65 | RAB9A (0.47) | ALDH1A1MAPT | |
| SCHEMBL27451739 | 0.64 | KCNA5 (0.37) | LMNAKCNA5ALDH1A1 | |
| SCHEMBL27046547 | 0.64 | SMN1; SMN2 (0.44) | LMNASMN1; SMN2L3MBTL1KCNA5ALDH1A1 | |
| SCHEMBL14931099 | 0.63 | RAB9A (0.47) | ALDH1A1 | |
| SCHEMBL4603000 | 0.63 | RAB9A (0.47) | ALDH1A1 | |
| SCHEMBL9467739 | 0.62 | CFTR (0.42) | LMNASMN1; SMN2L3MBTL1KCNA5KDM4E | |
| SCHEMBL7061205 | 0.62 | RAB9A (0.40) | LMNASMN1; SMN2L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153571-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153571-A1 | Method and composition for the treatment of pain | OPRK1, ACHE, OPRL1 | LMNA 2114/4885SMN1; SMN2 183/4885L3MBTL1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.